Basilar Artery OcclusionBAOCHE-LCNCT07345702
Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct
An observational study of Basilar Artery Occlusion and Ischemic Stroke, run by Xuanwu Hospital, Beijing at 1 site in China.
Trial summary
This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Basilar Artery Occlusion, Ischemic Stroke, Large Core Infarct
- What is being tested?
- Endovascular Therapy
- Type of treatment
- Surgery or procedure
- How many people
- 518 participants
- Where
- 1 siteChina
- Study dates
- 31 Jan 2026to 31 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults (≥18 years) with imaging-confirmed acute vertebrobasilar occlusion and large-core infarction (pc-ASPECTS 0-5) treated within 7 days of symptom onset/last known well at participating centers in China. Patients are identified retrospectively from routine clinical practice and classified according to treatment received: endovascular therapy plus standard medical management versus standard medical management alone.
Who may be able to join
- Age ≥18 years, men or women.
- Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
- Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.
- Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
Who cannot join
- Subjects with occlusions in both anterior and posterior circulation.
- CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
- Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset/last known well time, or missing major treatment information including whether EVT was performed).
- Baseline NIHSS score <6.
- Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
- Missing follow-up outcomes at 90 days.
- Any other condition judged by investigators to substantially affect analysis or interpretation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xuanwu Hospital
Beijing, Beijing Municipality, 100053
Chuanhui Li, 15210439828, lichuanhui@xwh.ccmu.edu.cn
About this study
Official title: Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)
This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.
- Being tested
- Endovascular Therapy
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endovascular TherapyProcedure or surgery
Endovascular therapy performed as part of routine clinical care for acute basilar artery occlusion, including mechanical thrombectomy with stent retriever and/or aspiration. Rescue angioplasty and/or intracranial stenting may be used at the operator's discretion. Peri-procedural management and concomitant medical therapy follow local standard practice.
| Study group | Role | What they receive |
|---|---|---|
| Endovascular Therapy | Not described Receives: Procedure: Endovascular Therapy | |
| Best Medical Treatment Alone | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Patients Achieving mRS 0-3 at 90 Days
The modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Higher scores mean a worse outcome.
Measured: 90 days
Secondary outcomes (4)
Ordinal Shift analysis of mRS at 90 days
The modified Rankin scale (range, 0 [no symptoms] to 6 [death])
Measured: 90 days
Rate of All-Cause Mortality at 90 Days
Death from any cause within 90 days.
Measured: 90 days
Rate of Symptomatic Intracranial Hemorrhage
Measured: 24 (-2/+12) hours
Proportion of Patients Achieving mRS 0-3 at 1 year
The modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Higher scores mean a worse outcome.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start31 Jan 2026
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Basilar Artery OcclusionStudies of the same condition, open and under way.
- More trials run by Xuanwu Hospital, BeijingThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 518 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xuanwu Hospital, Beijing
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chuanhui Li, Xuanwu Hospital, Beijing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07345702
- Sponsor's protocol ID
- BAOCHE-LC
- Acronym
- BAOCHE-LC
- Status last verified
- Jan 2026
- First submitted
- 7 Jan 2026
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The study is proceeding.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)
- ClinicalTrials.gov ID
- NCT07345702
- Acronym / sponsor ID
- BAOCHE-LC / BAOCHE-LC
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 518 participants (estimated)
- Lead sponsor
- Xuanwu Hospital, BeijingUniversity, hospital or other
- Study start
- 31 Jan 2026 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Oct 2026 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Endovascular Therapy | – | Procedure: Endovascular Therapy |
| Best Medical Treatment Alone | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults (≥18 years) with imaging-confirmed acute vertebrobasilar occlusion and large-core infarction (pc-ASPECTS 0-5) treated within 7 days of symptom onset/last known well at participating centers in China. Patients are identified retrospectively from routine clinical practice and classified according to treatment received: endovascular therapy plus standard medical management versus standard medical management alone.
Key inclusion criteria (4 listed)
- Age ≥18 years, men or women.
- Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
- Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.
- Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
Key exclusion criteria (7 listed)
- Subjects with occlusions in both anterior and posterior circulation.
- CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
- Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset/last known well time, or missing major treatment information including whether EVT was performed).
- Baseline NIHSS score <6.
- Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endovascular TherapyEndovascular therapy performed as part of routine clinical care for acute basilar artery occlusion, including mechanical thrombectomy with stent retriever and/or aspiration. Rescue angioplasty and/or intracranial stenting may be used at the operator's discretion. Peri-procedural management and concomitant medical therapy follow local standard practice. | Procedure or surgery | Endovascular Therapy |
Primary outcome
Proportion of Patients Achieving mRS 0-3 at 90 Days
Time frame: 90 days
The modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Higher scores mean a worse outcome.
4 secondary outcomes
Ordinal Shift analysis of mRS at 90 days
Time frame: 90 days
Rate of All-Cause Mortality at 90 Days
Time frame: 90 days
Rate of Symptomatic Intracranial Hemorrhage
Time frame: 24 (-2/+12) hours
Proportion of Patients Achieving mRS 0-3 at 1 year
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Individual participant dataSharing planned: No. The study is proceeding.
Related trials for Basilar Artery Occlusion
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
Acute Ischemic Stroke, Basilar Artery Occlusion
Recruiting
Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core
Acute Ischemic Stroke, Basilar Artery Occlusion
Recruiting
Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window
Acute Mild Ischemic Stroke, Basilar Artery Occlusion
Recruiting
EVT in Acute Basilar Artery Occlusion With Large Infarction Core
Basilar Artery Occlusion, Large Ischemic Core
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Basilar Artery Occlusion and Ischemic Stroke, run by Xuanwu Hospital, Beijing at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chuanhui Li (15210439828, lichuanhui@xwh.ccmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Patients Achieving mRS 0-3 at 90 Days (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.